SGEN — Seagen Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedLarge Cap
- $43.15bn
- $41.92bn
- $1.96bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.92 | ||
| Price to Tang. Book | 20.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 18.76 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.5% | ||
| Return on Equity | -27.93% | ||
| Operating Margin | -34.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 654.7 | 916.71 | 2,175.54 | 1,574.37 | 1,962.41 | 2,457.59 | 3,259.55 | 32.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Directors
- Clay Siegall CHM (60)
- Todd Simpson CFO (60)
- Jean Liu EVP (52)
- Lee Heeson EVP (52)
- Chip Romp EVP (53)
- Vaughn Himes CTO (60)
- Roger Dansey OTH (64)
- Felix Baker LED (52)
- David Gryska IND (64)
- Marc Lippman IND (76)
- Ted Love IND (62)
- John Orwin IND (55)
- Alpna Seth IND (58)
- Nancy Simonian IND (60)
- Daniel Welch IND (63)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- July 15th, 1997
- Public Since
- March 7th, 2001
- No. of Shareholders
- 51
- No. of Employees
- 3,256
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 188,662,672
- Address
- 21717 30th Drive S.E., Building 3, BOTHELL, 98021
- Web
- https://www.seagen.com/
- Phone
- +1 4255274000
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SGEN
Q1 2024 Seagen Inc Earnings Release
Seagen Inc Annual Shareholders Meeting
Similar to SGEN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Seagen share price?
As of Today at 06:19 UTC, shares in Seagen are trading at $228.74. This share price information is delayed by 15 minutes.
How has the Seagen share price performed this year?
Shares in Seagen last closed at $228.74 and the price had moved by +70.63% over the past 365 days. In terms of relative price strength the Seagen share price has outperformed the S&P500 Index by +39.28% over the past year.
What are the analyst and broker recommendations for Seagen?
The overall consensus recommendation for Seagen is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Seagen dividend yield?
Seagen does not currently pay a dividend.
Does Seagen pay a dividend?
Seagen does not currently pay a dividend.
When does Seagen next pay dividends?
Seagen does not currently pay a dividend.
How do I buy Seagen shares?
To buy shares in Seagen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Seagen?
As of the previous close price of $228.74, shares in Seagen had a market capitalisation of $43.15bn.
Where are Seagen shares listed?
Here are the trading details for Seagen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SGEN
What kind of share is Seagen?
Based on an overall assessment of its quality, value and momentum Seagen is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Seagen share price forecast for 2023?
The analyst consensus target price for shares in Seagen is $228.90. That is 0.07% above the last closing price of $228.74.
Analysts covering Seagen currently have a consensus Earnings Per Share (EPS) forecast of -$4.16 for the next financial year.
What is the trend in the Seagen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Seagen. Over the past six months, its share price has outperformed the S&P500 Index by +7.26%.
As of the last closing price of $228.74, shares in Seagen were trading +12.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Seagen PE Ratio?
The Seagen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $228.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Seagen?
Seagen's management team is headed by:
- Clay Siegall - CHM
- Todd Simpson - CFO
- Jean Liu - EVP
- Lee Heeson - EVP
- Chip Romp - EVP
- Vaughn Himes - CTO
- Roger Dansey - OTH
- Felix Baker - LED
- David Gryska - IND
- Marc Lippman - IND
- Ted Love - IND
- John Orwin - IND
- Alpna Seth - IND
- Nancy Simonian - IND
- Daniel Welch - IND